Overview of Fundamental Study of Pazopanib in Cancer

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2016 Jan 15

PMID 26767042

Citations 5

Authors

Hong-Lin Zhao

Fan Yang

Xin Huang

Qing-Hua Zhou

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is an indispensible process for tumor growth and metastasis. Anti-angiogenesis based therapy is one of the most promising treatments for inhibiting cancer progression. Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug. In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway, and directly targeted on v-raf murine sarcoma viral oncogene homolog B (B-raf) as well. It inhibited the proliferation of cell lines, such as DU-145 and HRC-45 in hepatocellular carcinoma, through mechanisms like "cell cycle arrest." In vivo xenograft studies and phase I/II clinical trials revealed a series of plasma cytokine and angiogenic factors, such as interleukin (IL)-6, IL-12, hepatocyte growth factor (HGF), and soluble VEGFR2, which have significant association with clinical curative effect. Pazopanib has been shown to be effective in solid tumors and some hematological malignancies. Future studies should focus on the exploration of biomarkers to screen sensitive patients and concomitant or metronomic dosage with other kinds of medicines.

Citing Articles

Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies.

Du Y, Li X, Ji S, Niu N Arch Toxicol. 2024; 99(1):67-81.

PMID: 39347999 DOI: 10.1007/s00204-024-03874-4.

Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors.

Singha M, Pu L, Stanfield B, Uche I, Rider P, Kousoulas K BMC Cancer. 2022; 22(1):1211.

PMID: 36434556 PMC: 9694576. DOI: 10.1186/s12885-022-10293-0.

Recent Advances in Age-Related Macular Degeneration Therapies.

Fabre M, Mateo L, Lamaa D, Baillif S, Pages G, Demange L Molecules. 2022; 27(16).

PMID: 36014339 PMC: 9414333. DOI: 10.3390/molecules27165089.

Laparoscopic Resection of a Left Upper Quadrant Mass Leading to a Surprise Diagnosis.

Bonatti H, Sahmel R, Erlich R Case Rep Surg. 2020; 2020:8365061.

PMID: 32566350 PMC: 7284930. DOI: 10.1155/2020/8365061.

Pazopanib in the management of advanced soft tissue sarcomas.

Cranmer L, Loggers E, Pollack S Ther Clin Risk Manag. 2016; 12:941-55.

PMID: 27354810 PMC: 4907704. DOI: 10.2147/TCRM.S84792.

References

Kumar R, Knick V, Rudolph S, Johnson J, Crosby R, Crouthamel M . Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6(7):2012-21. DOI: 10.1158/1535-7163.MCT-07-0193. View

Al-Marrawi M, Rini B . Pazopanib for the treatment of renal cancer. Expert Opin Pharmacother. 2011; 12(7):1171-89. DOI: 10.1517/14656566.2011.571206. View

Podar K, Tonon G, Sattler M, Tai Y, LeGouill S, Yasui H . The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006; 103(51):19478-83. PMC: 1748251. DOI: 10.1073/pnas.0609329103. View

Choueiri T, Fay A, Gagnon R, Lin Y, Bahamon B, Brown V . The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2013; 19(18):5218-26. PMC: 4522695. DOI: 10.1158/1078-0432.CCR-13-0491. View

Kumar S, Bayat Mokhtari R, Oliveira I, Islam S, Toledo S, Yeger H . Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts. Transl Oncol. 2013; 6(4):493-503. PMC: 3730024. DOI: 10.1593/tlo.13286. View

Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R . Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9(4):996-1006. PMC: 2852477. DOI: 10.1158/1535-7163.MCT-09-0960. View

Paesler J, Gehrke I, Gandhirajan R, Filipovich A, Hertweck M, Erdfelder F . The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res. 2010; 16(13):3390-8. DOI: 10.1158/1078-0432.CCR-10-0232. View

Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M . The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One. 2011; 6(10):e25625. PMC: 3187787. DOI: 10.1371/journal.pone.0025625. View

Nikolinakos P, Altorki N, Yankelevitz D, Tran H, Yan S, Rajagopalan D . Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010; 70(6):2171-9. PMC: 4512950. DOI: 10.1158/0008-5472.CAN-09-2533. View

10.

Roberts D, Kearney J, Johnson J, Rosenberg M, Kumar R, Bautch V . The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004; 164(5):1531-5. PMC: 1615669. DOI: 10.1016/S0002-9440(10)63711-X. View

11.

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

12.

Schoffski P . Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther. 2012; 12(6):711-23. DOI: 10.1586/era.12.41. View

13.

Harrison M . Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?. Clin Med Insights Oncol. 2011; 5:349-64. PMC: 3235998. DOI: 10.4137/CMO.S6087. View

14.

Pick A, Nystrom K . Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther. 2012; 34(3):511-20. DOI: 10.1016/j.clinthera.2012.01.014. View

15.

Keisner S, Shah S . Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011; 71(4):443-54. DOI: 10.2165/11588960-000000000-00000. View

16.

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F . Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3):220-31. PMC: 2874829. DOI: 10.1016/j.ccr.2009.01.027. View

17.

Lohela M, Bry M, Tammela T, Alitalo K . VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009; 21(2):154-65. DOI: 10.1016/j.ceb.2008.12.012. View

18.

Liekens S, De Clercq E, Neyts J . Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001; 61(3):253-70. DOI: 10.1016/s0006-2952(00)00529-3. View

19.

Hurwitz H, Dowlati A, Saini S, Savage S, Suttle A, Gibson D . Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009; 15(12):4220-7. DOI: 10.1158/1078-0432.CCR-08-2740. View

20.

Tran H, Liu Y, Zurita A, Lin Y, Baker-Neblett K, Martin A . Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012; 13(8):827-37. DOI: 10.1016/S1470-2045(12)70241-3. View